TY - JOUR
T1 - Therapeutic Effect of
Bifidobacterium Administration on
Experimental Autoimmune
Myasthenia Gravis in Lewis Rats
AU - Rinaldi, Elena
AU - Consonni, Alessandra
AU - Cordiglieri, Chiara
AU - Sacco, Grazia
AU - Crasà, Camilla
AU - Fontana, Alessandra
AU - Morelli, Lorenzo
AU - Elli, Marina
AU - Mantegazza, Renato
AU - Baggi, Fulvio
PY - 2019
Y1 - 2019
N2 - Beneficial effects of probiotics on gut microbiota homeostasis and inflammatory immune
responses suggested the investigation of their potential clinical efficacy in experimental
models of autoimmune diseases. Indeed, administration of two bifidobacteria and
lactobacilli probiotic strains prevented disease manifestations in the Lewis rat model
of Myasthenia Gravis (EAMG). Here, we demonstrate the clinical efficacy of therapeutic
administration of vital bifidobacteria (i.e., from EAMG onset). The mechanisms involved in
immunomodulation were investigated with ex vivo and in vitro experiments. Improvement
of EAMG symptoms was associated to decreased anti-rat AChR antibody levels, and
differential expression of TGFb and FoxP3 immunoregulatory transcripts in draining
lymph nodes and spleen of treated-EAMG rats. Exposure of rat bone marrow-derived
dendritic cells to bifidobacteria or lactobacilli strains upregulated toll-like receptor 2
mRNA expression, a key molecule involved in bacterium recognition via lipotheicoic acid.
Live imaging experiments of AChR-specific effector T cells, co-cultured with BMDCs
pre-exposed to bifidobacteria, demonstrated increased percentages of motile effector
T cells, suggesting a hindered formation of TCR-peptide-MHC complex. Composition
of gut microbiota was studied by 16S rRNA gene sequencing, and a and b diversity
were determined in probiotic treated EAMG rats, with altered ratios between Tenericutes
and Verrucomicrobia (phylum level), and Ruminococcaceae and Lachnospiraceae (family
level). Moreover, the relative abundance of Akkermansia genus was found increased
compared to healthy and probiotic treated EAMG rats. In conclusion, our findings
confirms that the administration of vital bifidobacteria at EAMG onset has beneficial
effects on disease progression; this study further supports preclinical research in human
MG to evaluate probiotic efficacy as supplementary therapy in MG.
AB - Beneficial effects of probiotics on gut microbiota homeostasis and inflammatory immune
responses suggested the investigation of their potential clinical efficacy in experimental
models of autoimmune diseases. Indeed, administration of two bifidobacteria and
lactobacilli probiotic strains prevented disease manifestations in the Lewis rat model
of Myasthenia Gravis (EAMG). Here, we demonstrate the clinical efficacy of therapeutic
administration of vital bifidobacteria (i.e., from EAMG onset). The mechanisms involved in
immunomodulation were investigated with ex vivo and in vitro experiments. Improvement
of EAMG symptoms was associated to decreased anti-rat AChR antibody levels, and
differential expression of TGFb and FoxP3 immunoregulatory transcripts in draining
lymph nodes and spleen of treated-EAMG rats. Exposure of rat bone marrow-derived
dendritic cells to bifidobacteria or lactobacilli strains upregulated toll-like receptor 2
mRNA expression, a key molecule involved in bacterium recognition via lipotheicoic acid.
Live imaging experiments of AChR-specific effector T cells, co-cultured with BMDCs
pre-exposed to bifidobacteria, demonstrated increased percentages of motile effector
T cells, suggesting a hindered formation of TCR-peptide-MHC complex. Composition
of gut microbiota was studied by 16S rRNA gene sequencing, and a and b diversity
were determined in probiotic treated EAMG rats, with altered ratios between Tenericutes
and Verrucomicrobia (phylum level), and Ruminococcaceae and Lachnospiraceae (family
level). Moreover, the relative abundance of Akkermansia genus was found increased
compared to healthy and probiotic treated EAMG rats. In conclusion, our findings
confirms that the administration of vital bifidobacteria at EAMG onset has beneficial
effects on disease progression; this study further supports preclinical research in human
MG to evaluate probiotic efficacy as supplementary therapy in MG.
KW - EAMG
KW - Immunoregulation
KW - MG
KW - Probiotics
KW - therapeutic treatment
KW - EAMG
KW - Immunoregulation
KW - MG
KW - Probiotics
KW - therapeutic treatment
UR - http://hdl.handle.net/10807/164342
U2 - 10.3389/fimmu.2019.02949
DO - 10.3389/fimmu.2019.02949
M3 - Article
SN - 1664-3224
VL - 10
SP - 1
EP - 17
JO - Frontiers in Immunology
JF - Frontiers in Immunology
ER -